Will NeuroPace ’s RNS System Shock the Obesity Treatment Market?

This study will evaluate whether neurostimulation can automatically respond to the signals that occur immediately before a loss-of-control eating episode to help patients regain control, a potentially groundbreaking intervention for the most severely affected patients. The RNS System’s ability to continuously monitor brain activity and respond with therapy when these biomarkers are detected makes the system an ideal fit for this research.” Changes in the Market With this study, NeuroPace is venturing out into new territory. Typically, the firm’s closed-loop neuromodulation technology is used to treat adults with medically refractory focal onset epilepsy.MD+DIreported in 2013 that NeuroPace landed a PMA from FDA for the RNS System. If the investigators are successful, then NeuroPace’s technology could be transformative for the ever-shifting obesity treatment market. Companies in the space have gone through significant changes in the last few months. Competition has ramped up; there has been a change in sales models; and product swaps. Obalon has made some changes recently that might have left some in the industry puzzled. In April, the San Diego, CA-based company cut staff by 50% in a move that included the elimination of its direct sales force and a reduction in headquarters staff. Obalon said it was jettisoning off its sales force to transition to a new selling model intended to efficiently use the exist...
Source: MDDI - Category: Medical Devices Authors: Tags: R & D Source Type: news